Besides, compared with the biomacromolecules, such as CD28-B7-1/CD28-B7-2 signals, it would contribute to bioprospect less immunogenic and better penetrated natural molecules to break a novel field of natural products activated tumor-specific T-cell therapy (Nat-T cell therapy). The gene discussed is CD86; the disease is neoplasm.